Tumors are complex tissues made up of not only cancer cells but also normal cells from the surrounding tissue that get recruited to the tumor microenvironment. These cells include fibroblasts, immune cells, pericytes and endothelial cells.
Cancer cells send out molecular signals that influence normal cells in the area. For example, they secrete growth factors that stimulate angiogenesis – the formation of new blood vessels. They recruit fibroblasts and signal them to undergo changes that help tumors grow and spread. Cancer cells also alter immune cells in ways that dampen the body’s natural antitumor responses.
At the same time, normal cells in the Tumor Microenvironment influence cancer progression through direct cell-cell contact or secretions of their own. Fibroblasts secrete proteins that support tumor growth, invasion and metastasis. Immune cells may promote cancers through chronic inflammation. Endothelial cells and pericytes help tumors develop their blood supply through angiogenesis.
Understanding these intricate interactions between cancer cells and normal cells in the microenvironment is crucial for developing new targeted therapies. Blocking certain signaling pathways or recruiting specific immune cells could help fight tumors by altering their microenvironment.
How the Extracellular Matrix Affects Cancer Development
The extracellular matrix (ECM) provides structural support to tissues and participates in cellular communication. In the tumor microenvironment, abnormalities in ECM composition and remodeling influence multiple steps of cancer progression.
Fibroblasts produce an abnormal matrix rich in fibrillar collagens, fibronectin and proteoglycans. This dense matrix physically compresses tumor vessels and restricts immune cell movement. It also influences tumor cell behavior through integrin-mediated signaling.
Matrix-degrading enzymes like MMPs are abundant. While allowing tumors to grow unchecked, their action releases soluble factors like TGF-beta from ECM stores, further fostering cancer growth and metastasis. MMPs also activate pro-cytokines and pro-growth factors within the matrix.
The abnormally stiff matrix creates elevated pressure within Tumor Micronvironment. This forces cancer cells to migrate away from the primary site along paths of least resistance. It may also activate certain growth-promoting signaling pathways in cancer cells.
Reducing matrix stiffness or altering its composition could block tumor progression. Drugs targeting specific ECM components and remodeling enzymes are being studied as anticancer strategies.
Inflammation and the Role of Immune Cells in Tumors
The tumor microenvironment often exhibits a smoldering form of chronic inflammation. Immune cells contribute to this as well as influence cancer behaviors.
Tumors enlist immunosuppressive cells like regulatory T cells and myeloid-derived suppressor cells to dampen immune responses. They also hinder cytotoxic T cells, natural killer cells and antigen presentation.
Some immune cell populations, especially tumor-associated macrophages, may promote cancer at certain stages by secreting growth factors, cytokines and proteases. They help remodeling of the stroma, angiogenesis and pre-metastatic niche formation.
However, immune cells could potentially attack cancers if appropriately activated. Research reveals ways to modulate immune checkpoints, license dendritic cells for vaccination or recruit natural killer cells. Therapies now exploit these mechanisms using antibodies, immune cell therapies and vaccines.
The delicate balance between pro- and anti-tumor immunity is crucial. Understanding immune dynamics in the tumor microenvironment remains a top priority for improving immunotherapies.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it